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Running title: MAIT cell development.  
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T cells play key roles in the immune system by detecting microbial molecules associated with 
infection. One major T cell population, mucosal-associated invariant T (MAIT) cells, are 
activated by microbial vitamin B2 (riboflavin) derivatives presented by the major 
histocompatibility complex (MHC) class I related protein, MR1
1-4
. In humans, MAIT cells 
represent between 5 and 50% of T cells in different human tissues 
5-8
. The number of MAIT 
cells varies widely between individuals and the factors that govern the development of these 
cells are unclear. Using MR1 tetramers to detect MAIT cells in mice and humans, we have now 
identified thymic precursors to the MAIT cell lineage and delineated three distinct stages in 
MAIT cell development. In mice, the least mature, stage 1 (CD24
+
CD44
-
) cells progress to an 
intermediate stage 2 (CD24
-
CD44
-
) before maturing into stage 3 (CD24
-
CD44
+
) MAIT cells. 
Progression through each of these checkpoints is MR1 dependent, while the final maturation 
checkpoint that gives rise to functional MAIT cells requires the transcription factor, 
promyelocytic leukemia zinc finger (PLZF). In humans, stage 1 (CD161
-
CD27
-
) and stage 2 
MAIT cells (CD161
-
CD27
+
) predominate in the thymus, while stage 3 cells (CD161
+
) 
progressively increase in percentage in umbilical cord blood, young peripheral blood and adult 
peripheral blood. MAIT cell maturation can also occur after thymic emigration of immature 
MAIT cells in both humans and mice. Accordingly, this study maps the intrathymic 
developmental pathway and identifies key checkpoints that control the maturation of 
functional MAIT cells in mice and humans.  
 
Recent studies have indicated that MAIT cells play unique and important roles in the immune system 
in response to infection with a broad range of pathogens
6,9,10
 and they may also be involved in 
autoimmunity and other inflammatory responses
24
. Previous studies have demonstrated that MAIT 
cells are thymus dependent
4
, MR1-restricted cells
1
, that undergo positive selection and lineage 
commitment upon interaction with MR1-expressing CD4
+
CD8
+
 cortical thymocytes
11
. With the 
recent development of MR1 tetramers loaded with riboflavin derivatives such as 5-OP-RU 
2,12,13,15
, it 
is now possible to specifically identify and isolate MAIT cells in mice and humans. Here, we 
examined the developmental pathway of MAIT cells, and identified a previously undescribed 
population of CD24
+
CD44
-
 MAIT cells in mouse thymus but not in peripheral organs, where 
essentially all MAIT cells were CD24
-
CD44
+
 (Figure 1a). Single cell TCR sequence analysis of both 
populations of thymic MAIT cells showed that they utilized an invariant Vα19Jα33 (TRAV1 
TRAJ33) TCR-α chain, paired with a limited range of TCR-β chains (TRBV13 and TRBV19) that 
are characteristic of the MAIT cell lineage
4
 (Supplementary Table 1). Characterisation of 
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CD24
+
CD44
- 
and CD24
-
CD44
+
 MAIT cells within the thymus revealed contrasting phenotypes 
(Figure 1b and Supplementary Table 2). CD24
+
CD44
- 
MAIT cells expressed low levels of PLZF, 
CD103, CD122 (IL-2Rβ), CD127 (IL-7Rα), CD218 (IL-18R), CD278 (ICOS) and CD161 (NK1.1), 
but higher levels of CD62L and CD69 compared to CD24
-
CD44
+ 
MAIT cells (Figure 1b). 
Enrichment of thymic MR1-5-OP-RU tetramer
+
 cells identified an additional small subpopulation of 
CD24
-
CD44
-
 MAIT cells (Figure 1c), thus, we tentatively defined these populations as stage 1 
(CD24
+
CD44
-
), stage 2 (CD24
-
CD44
-
) and stage 3 (CD24
-
CD44
+
) MAIT cells (Figure 1). Analysis 
of forward scatter (FSC), CD4 and CD8 expression on these thymic MAIT cell populations showed 
that the vast majority of stage 1 MAIT cells were small and CD4
+ 
or
 
CD4
+
CD8
+
, a phenotype that is 
typically associated with immature cells in the thymus and that also defines the earliest stage in the 
development of CD1d-restricted Natural Killer T (NKT) cells
14
. Stage 2 cells were slightly larger, 
mostly CD4
+
CD8
-
, whereas stage 3 MAIT cells were the largest and resemble mature MAIT cells in 
peripheral organs, being mostly CD4
-
CD8
-
 or CD8
+
 (Figure 1c).
 
Collectively, our data supports the 
presence of at least three distinct stages of MAIT cell development within mouse thymus.  
 
To investigate their developmental progression, we carried out an ontogeny study for MAIT cell 
subsets in mouse thymus at 2, 4 and 8 weeks of age. Stage 1 MAIT cells were the major subset 
(>50%) in the very young mouse thymus at 2 weeks, declining to ~30% at 4 weeks and just ~10% of 
total thymic MAIT cells in the adult 8 week old mouse thymus (Figure 2a and b). Conversely, the 
proportion of stage 3 MAIT cells was low (~20%) at 2 weeks and gradually increased with age 
(~60% at 4 weeks and ~80% at 8 weeks) (Figure 2a and b), supporting the developmental 
progression of MAIT cells from stage 1 to stage 3. To determine at which stage MAIT cells gain 
functional maturity, we examined the three maturation stages for production of IL-17 and IFN-γ, 
cytokines typically expressed by mouse MAIT cells following stimulation
15
. Only the most mature, 
stage 3 MAIT cells from the thymus produced cytokines in this assay (Figure 2c). Accordingly, the 
loss of CD24 and the acquisition of CD44 correlate with the functional potential of mouse MAIT 
cells.  
 
To directly investigate the precursor/progeny relationship of these subsets, we established an in vitro 
MAIT cell development system, using an adaptation of the OP9 cell-thymocyte co-culture system
16
. 
Because the numbers of thymus MAIT cell subsets in wild type mice were very low, we initially 
used Vα19 TCR transgenic Cα-/- mice where the three stages of thymus MAIT cells were far more 
abundant (Supplementary Figure 1), thus allowing us to isolate sufficient numbers of these cells for 
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in vitro differentiation studies. After 5 days of co-culture with OP9 cells, purified stage 1 MAIT cells 
had started to differentiate into stage 2 and stage 3 cells (Figure 2d and e). Similarly, the stage 2 cells 
had progressed further toward stage 3, whereas the stage 3 cells maintained their mature CD24
-
CD44
+
 phenotype (Figure 2d and e). Importantly, in control cultures lacking OP9 cells, no MAIT 
cell differentiation was observed, indicating the importance of stromal cell-derived factors in the 
MAIT cell differentiation process. We also tested OP9 cells engineered to express the Notch ligand, 
Delta-like 1, (OP9-DL1). Similar to the maturation of γδ T cells from γδTCR-expressing T cell 
precursors
17
, signalling through DL1 was not required for maturation of TCR
+
 MAIT cell precursors 
(data not shown) hence, parental OP9 cells were used for subsequent experiments. The presence of 
anti-MR1 blocking antibody completely inhibited the progression of stage 1 to stage 3 MAIT cells, 
and partially inhibited the differentiation or survival of stage 2 and stage 3 cells, as reflected by a 
sharp reduction in cell numbers by the end of culture (Figure 2d and e). These data are consistent 
with the lack of MAIT cells in MR1-deficient mice 
1,8,15
, but also highlight that the expression of 
MR1 is critical for both the initial development and further differentiation of MAIT cells. 
 
Having established this differentiation sequence using Vα19 TCR transgenic MAIT cells, we next 
undertook similar experiments using MAIT cell subsets from wild type mice (Figure 2d). Because 
these cells were much less frequent, we were unable to isolate sufficient numbers of the intermediate 
stage 2 cells, but nonetheless, the results of culturing stage 1 and stage 3 MAIT cells matched those 
observed with the Vα19 TCR transgenic cells (Figure 2d and e). Thus, stage 1 cells progressed to 
stages 2 and 3 after 5 days of co-culture with OP9 cells, whereas stage 3 cells maintained their 
mature phenotype. Taken together, these data confirm that differentiation of mouse MAIT cells can 
be defined by a three-stage sequential pathway from CD24
+
CD44
- 
(stage 1), via CD24
-
CD44
- 
(stage 
2), to CD24
-
CD44
+
 (stage 3).  
 
The transcription factor PLZF, known to be important for the development of NKT cells, ILC cells 
and some γδ T cells18-21 is expressed by MAIT cells in humans and mice8,15. We recently determined 
that the production of normal numbers of MAIT cells depends upon this factor, although notably, a 
residual population of MAIT cells remained in PLZF-deficient mice
15
. Using wild type mice, we 
determined that this transcription factor is first expressed on stage 2 MAIT cells, which were 
heterogeneous for PLZF expression, and fully expressed by stage 3 (Figure 3a). Examination of 
PLZF knockout (KO) mice revealed that the stage 1 and stage 2 MAIT cell compartments were 
intact, whereas stage 3 MAIT cells were completely absent (Figure 3b and c). Even in peripheral 
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tissues, the residual MAIT cells were also blocked at stage 2 including a predominantly CD4
+
CD8
-
 
phenotype (Figure 3b), and lack of CD218, CD127 and CD103 expression (data not shown), thus 
resembling immature MAIT cells as shown in (Figure 1b). This suggests that the progression to stage 
2 is PLZF independent but maturation of stage 2 to stage 3 is absolutely dependent on PLZF, and 
furthermore this can occur after stage 2 cells leave the thymus. In the absence of the PLZF driven 
maturation signal, stage 2 MAIT cells remain immature in both thymus and peripheral tissues. 
 
Given that MAIT cells in mouse thymus could be delineated into three phenotypically and 
functionally distinct stages, it was important to determine whether MAIT cells followed a similar 
developmental pathway in humans. Our initial studies involved using human MR1-5-OP-RU 
tetramers along with surrogate phenotypic markers Vα7.2, CD161 and CD218, which are commonly 
used to identify MAIT cells in humans
5,8,13,22-24
. We detected MAIT cells (defined as Vα7.2+ MR1-
5-OP-RU tetramer
+
) in all human thymus samples tested, and found these cells to be much less 
frequent (<0.05%) than in adult human blood where they typically represent 2-5% of T cells (Figure 
4a and 
15
), and they were therefore difficult to detect amongst whole thymocyte preparations. 
However, when we enriched for Vα7.2+ cells using magnetic bead enrichment, a clear population of 
MAIT cells was detected, ranging from 0.08-0.45% of Vα7.2+ thymocytes (Figure 4a and b). 
Examination of thymic MAIT cells for CD161 and CD218 revealed a markedly distinct cell surface 
phenotype compared to those from adult peripheral blood, umbilical cord blood and matched young 
peripheral blood taken from the thymus donors. The vast majority of MAIT cells from the blood of 
adult and young donors co-expressed CD218 and CD161 at high levels and were predominantly 
CD4
-
CD8
-
 or CD4
-
CD8
+
 (Figure 4a), consistent with previous findings
5,8,13,23
. In contrast, the vast 
majority of MAIT cells from the thymus were CD218
-
CD161
-
, ranging from 40-97% of all thymic 
MAIT cells (Figure 4a and b), suggesting that CD218
-
CD161
- 
MAIT cells represent a major 
immature precursor population within human thymus.  
 
These results showed a clear and significant difference in the phenotype of MAIT cells, based on 
expression of CD218 and CD161 and CD4/CD8 co-receptor expression in human thymus compared 
to donor-matched peripheral blood (Figure 4a-d). These observations strongly suggest that MAIT 
cells in the thymus are predominantly immature and that further maturation, either just prior to, or 
soon after, thymic emigration occurs in humans. To further investigate where this maturation occurs, 
we examined cord blood samples as a source of MAIT cells, since in this compartment they should 
be enriched for recent thymic emigrants (Figure 4a-c). MAIT cells were detectable in all samples, 
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albeit at low frequencies ranging from 0.006-0.02% of total cells (0.3-0.9% of Vα7.2+ T cells), and 
were therefore similar to thymus and distinct from adult peripheral blood in terms of frequency 
(Figure 4a and b). These cells were heterogeneous for CD218 and CD161 and expressed higher 
proportions of CD4
+
, but lacked CD4
+
CD8
+
 MAIT cells (Figure 4a). Thus, MAIT cells that have 
recently emigrated from the thymus were a mixture of immature thymus-like cells and mature, 
peripheral blood-like cells.  
 
Immature CD161
-
 MAIT cells could be further divided based on CD27 expression, allowing us to 
fractionate MAIT cells into three stages that closely resembled their mouse counterparts. CD161
-
CD27
-
 MAIT cells were mostly CD4
+
 or CD4
+
CD8
+
, PLZF
lo
, and were only detected in human 
thymus (Figure 4a, e and f). CD161
-
CD27
+
 MAIT cells appeared to be more mature with less 
CD4
+
CD8
+
 and more CD4
-
CD8
+
; they expressed low to intermediate levels of PLZF, and they were 
detected at low frequency in cord blood (22±2%) and young blood (13±4%) but were essentially 
absent from adult blood (0.9±0.3%) (Figure 4a, d and f). In contrast, CD161
+
CD27
+/-
 MAIT cells 
were mostly CD4
-
CD8
-
 or CD8
+
 (Figure 4f), PLZF
+
, and were very similar to MAIT cells found in 
human peripheral blood (Figure 4a). Taken together, these data suggested that CD161
-
CD27
-
 MAIT 
cells are the least mature (stage 1), followed by CD161
-
CD27
-
 cells (stage 2) that are capable of 
emigrating from the human thymus and continuing their maturation extrathymically, giving rise to 
CD161
+
CD27
+/-
 (stage 3) cells, that resemble MAIT cells detected in adult peripheral tissues. This is 
reminiscent of CD1d-restricted NKT cells in humans, which also undergo their final maturation 
(upregulation of CD161 and downregulation of CD4) extrathymically
25
. Based on the large increase 
in the frequency of MAIT cells after they leave the thymus, it is likely that their numbers increase in 
the periphery, possibly in response to microbial antigens, as has been previously reported in mice
1
. 
Our data provide a very different perspective of human MAIT cell development to that of two 
previous studies where immature MAIT cells were described as predominantly CD4
-
 
8,26
. This is
 
likely due to the use of surrogate phenotypic markers such as CD161
+
 and Vα7.2+, which would 
exclude the vast majority of immature MAIT cells or include non-MAIT cells.  
 
We have defined thymic precursors for the MAIT cell lineage and mapped a three-stage 
developmental pathway for MAIT cell development and maturation in mice and humans. We 
propose that these transitions are regulated by developmental checkpoints (Supplementary Figure 2): 
Checkpoint 1 occurs in the thymus, and controls initial commitment to the MAIT cell lineage (stage 
1 MAIT cells) and is absolutely dependent on MR1; Checkpoint 2 (transition from stage 1 to stage 2) 
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also occurs in the thymus and requires ongoing interactions with MR1 as well as stromal cell factors; 
Checkpoint 3, governs the final maturation step from stage 2 to stage 3, is absolutely dependent on 
the transcription factor PLZF and requires ongoing contact with MR1 for optimal efficiency, but this 
transition can occur both intrathymically and extrathymically (Supplementary Figure 2). In summary, 
our study has mapped a three-stage, three-checkpoint process for MAIT cell development, and will 
serve as the basis for understanding the impact of factors that regulate this highly abundant, yet 
highly variable, T cell lineage.  
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Methods 
Mice.  
C57BL/6 (B6) mice, MR1 KO mice, and Vα19 TCR transgenic Cα-/- mice (all on a C57BL/6 
background) were bred in house at the Department of Microbiology and Immunology Animal House, 
University of Melbourne. PLZF KO mice were generated and bred in house at the John Curtin 
School of Medical Research as previously described (15). All procedures using mice were approved 
by the University of Melbourne Animal Ethics Committee or the Australian National University 
Animal Experimentation Ethics Committee. Single cell suspensions from mouse thymus, spleen, 
lung and inguinal lymph nodes were prepared as previously described
15
. 
 
Human blood and tissue  
Adult peripheral human blood samples were obtained from the Australian Red Cross Blood Service 
under agreement number 13-04VIC-07. Young human peripheral blood samples and matching 
thymus (young donors ranged from 2 days to 12 years of age) were obtained from the Royal 
Children’s Hospital (RCH), Victoria, Australia. Umbilical cord blood samples were obtained from 
the Mercy Hospital for Women, Victoria, Australia. Experiments were conducted in accordance with 
University of Melbourne Human Research and Ethics committee guidelines (reference numbers 
1035100 and 1443540), Mercy Health Human Research Ethics Committee Approval (reference 
number R14/25) and RCH Human Research Ethics Committee Approval (reference number 24131 
G). Blood mononuclear cells were isolated by Ficoll-Paque Plus
TM
 density gradient centrifugation 
(GE Healthcare). Donor thymii were cut into small pieces and passed through a 70 micron cell 
strainer into ice-cold RPMI-1640 medium containing 2mM EDTA before being washed into PBS + 
2% Fetal Calf Serum (FACS buffer). 
 
Magnetic bead enrichment of thymic MAIT cells. 
Mouse and human MR1 tetramers were generated and biotinylated as previously described
2,12
. 
Biotinylated MR1-5-OP-RU or control or Ac-6FP monomers were tetramerized with streptavidin 
conjugated to either PE (SA-PE) (BD Pharmingen) or Brilliant Violet 421 (SA-BV) (Biolegend). 
Single cell suspensions of mouse thymus were prepared and stained with PE-mouse MR1-5-OP-RU 
tetramers prior to magnetic bead enrichment using anti-PE microbeads as per manufacturer’s 
instructions (Miltenyi Biotec). One independent enriched sample contains 5 pooled thymii. Single 
cell suspensions of human thymus were enriched for Vα7.2+ cells by staining for Vα7.2-PE antibody, 
followed by magnetic bead enrichment using anti-PE microbeads (Miltenyi Biotec). 
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Single cell TCR sequencing. 
MR1-5-OP-RU tetramer
+
 cells were single cell sorted based on CD24 and CD44 expression and 
cDNA prepared using SuperScript VILO (Invitrogen) as per manufacturer's instructions. Transcripts 
encoding different Vα and Vβ genes were amplified using multiplex nested PCR as previously 
described
27
. PCR products were separated using a 1.5% agarose gel and sequenced by The Molecular 
Diagnostics Unit, University of Melbourne.  
 
Flow Cytometry. 
Mouse and human cells were stained with viability dye 7-aminoactinomycin D (7-AAD; Sigma) and 
the following cell surface antibodies. Mouse: TCRβ (H57-597, BD Pharmingen), CD4 (RM4-5, 
Biolegend), CD8 (53-6.7, BD Pharmingen), CD24 (M1/69, BD Pharmingen), CD44 (IM7, BD 
Pharmingen, eBioscience), CD62L (MEL-14, eBioscience), CD69 (H1.2F3, eBioscience), CD103 
(2E7, Biolegend), CD127 (IL-7R A7R34, eBioscience), CD218 (IL-18Rα BG, Biolegend), NK1.1 
(PK136, BD Pharmingen) and B220 (RA3-6B2, BD Pharmingen). Human: CD3ε (UCHT1, BD 
Biosciences), CD4 (OKT4, Biolegend), CD8α (SK1 Biolegend), CD14 (M5E2, Biolegend), CD19 
(HIB19, Biolegend), CD27 (O323, Biolegend), CD161 (HP-3G10, Biolegend), IL-18Rα (H44, 
Biolegend) and Vα7.2 (3C10, Biolegend). Mouse cells are gated on B220
-
 lymphocytes and human 
cells on CD14
-
 CD19
-
 lymphocytes after dead cell and doublet exclusion. Cells were analysed using 
a BD LSR Fortessa equipped with a 561nm yellow-green laser and data processed using FlowJo 
software (Treestar). Mouse MAIT cells were sorted using a BD FACSAriaIII cell sorter. 
 
Intracellular cytokine and intracellular transcription factor staining. 
Briefly, magnetic bead enriched MR1-5-OP-RU tetramer
+
 cells from mouse thymus were stimulated 
for 4h with PMA (10 ng/ml) and ionomycin (1 µg/ml) in the presence of GolgiStop (BD 
Biosciences). Surface staining of the cells was then performed, before the cells were fixed and 
permeabilized using BD Cytofix/Cytoperm kit (BD Biosciences) as per manufacturer’s instructions. 
Cells were then stained for intracellular cytokines with anti-IFN-γ (XMG1.2, BD Pharmingen) and 
anti-IL-17A (TC11-18H10, BD Pharmingen) prior to flow cytometric analysis. PLZF was assessed 
by staining with the anti-PLZF antibody (Mags.21F7, eBioscience) after the cells were surface-
stained and permeabilized with the eBioscience Foxp3 Fixation/Permeabilization kit, according to 
the manufacturer’s instructions.  
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OP9 co-culture differentiation assay. 
To verify the precursor-product relationship of mouse MAIT cells, an adaptation of the OP9 co-
culture protocol previously described
25
 was used. Briefly, OP9 cells were plated in 96 well plates 
using DMEM media supplemented with 10% (v/v) Fetal Calf Serum (FCS), 1x GlutaMAX
TM
 (2mM 
L-Glutamine, Gibco) 15mM HEPES (Gibco), 0.1mM NEAA (non-essential amino acids, Invitrogen), 
100U/ml penicillin (sodium salt, Gibco), 1mM sodium pyruvate (Invitrogen), 100µg/ml streptomycin 
sulfate (Gibco) and 50µM 2-mercaptoethanol (Sigma). 1x10
4
 sorted MAIT cells from various stages 
(Stage 1, 2 and 3) were cultured in the presence or absence of OP9 cells with identical media 
supplemented with mouse IL-2 (50ng/ml, Peprotech). MR1 blocking antibody (clone 8F2.F9)
28
 was 
added at 10µg/ml. MAIT cells were harvested after 5 days, stained with antibodies and analysed by 
flow cytometry.  
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Figure Legends 
 
Figure 1. Identification of distinct MAIT cell subsets in mouse thymus.  
Flow cytometry analysis of MR1-5-OP-RU tetramer reactive MAIT cells for expression of CD24, 
CD44, CD4 and CD8 in adult mouse thymus, spleen, lung and lymph nodes.  MR1-Ac-6-FP tetramer 
was used as a negative control. Data are representative of a total of 6 mice from 3 independent 
experiments. (b) Phenotypic analysis of CD24
+
CD44
-
 and CD24
-
CD44
+
 thymic MAIT cells with 
ICOS, CD161 (NK1.1), CD62L, CD69, CD103, CD122 (IL-2R), CD127 (IL-7R) and CD218 (IL-
18R), CD24
+
CD44
-
 MAIT cells in blue, CD24
-
CD44
+
 MAIT cells in red, CD4
+
CD8
+
 double positive 
thymocytes in black. Data from 5 pooled mice from each experiment and is representative of 2 
independent experiments for each phenotypic marker. (c) Identification of three populations of 
thymic MAIT cells following magnetic bead enrichment. Flow cytometry analysis of 3 stages of 
MAIT cells defined using CD24 and CD44. Stage 1 (CD24
-
CD44
+
) in blue, stage 2 (CD24
-
CD44
-
) in 
green and stage 3 (CD24
-
CD44
+
) in red. Forward scatter (FSC) and CD4/CD8 co-receptor 
expression on stage 1, stage 2 and stage 3 MAIT cells. Data are representative of at least 10 
independent experiments 
 
Figure 2. Precursor product relationship of mouse MAIT cells 
(a) Thymii from 2 week, 4 week and 8-week old C57BL/6 mice were pooled, enriched for MR1-5-
OP-RU tetramer
+
 cells and analyzed for CD24 and CD44 expression. Data are representative of 4 
independent samples per age group. (b) Percentages of stage 1, stage 2 and stage 3 MAIT cells in 2 
week, 4 week, and 8-week old mice thymii and the bar depicts the mean ± SEM from 4 independent 
samples. (c) Enriched mouse thymocytes were stimulated for 4h in presence of PMA/ionomycin, 
labeled with MR1-5-OP-RU tetramer and surface antibodies, fixed and permeabilized and then 
stained with anti-IFN-γ or IL-17A. Data are representative of 3 independent experiments. (d) CD24
-
CD44
+
 MAIT cells develop from stage 1 CD24
+
CD44
-
 and stage 2 CD24
-
CD44
-
 precursors. Stage 1, 
stage 2 and stage 3 MAIT cells from Vα19 TCR transgenic (TG) mouse thymii, and stage 1 and 
stage 3 MAIT cells from wild type mouse thymii, were purified by flow cytometric sorting (day 0) 
and cultured in the presence or absence of OP9 cells, with or without anti-MR1 antibody. Cultures 
were harvested on day 5 and MAIT cells examined for CD24 and CD44 expression. Data are 
representative of 3 independent experiments. (e) Percentages and numbers of stage 3 MAIT cells at 
the end of culture. Bars depict mean ± SEM for 3 independent experiments.   
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Figure 3. PLZF controls development of MAIT cells 
(a) PLZF expression on stage 1, stage 2 and stage 3 cells from enriched C57BL/6 wild type  (WT) 
mouse thymus. (b) Analysis of MAIT cells from spleen, lymph node or enriched thymus from 
C57BL/6 WT and PLZF knockout (KO) mice. Cells were examined for CD24, CD44, and CD4/CD8 
co-receptor expression using flow cytometry. Data are representative of 3 independent experiments 
with a total of 9 mice per group. (c) Percentages of stage 1, stage 2 and stage 3 MAIT cells in 
enriched thymus, spleen and lymph nodes of WT and PLZF KO mice. Bars depict mean ± SEM, data 
are representative of 3 independent experiments with a combined total of 9 mice per group *P<0.1 
**P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test.  
 
Figure 4. Identification of distinct MAIT cell subsets in humans 
(a) Flow cytometric analysis of adult peripheral blood samples, human thymus samples enriched for 
Vα7.2
+
 cells, young peripheral blood samples matched from the thymus donors, and donor cord 
bloods. The first two panels depict CD3
+
 lymphocytes, stained with anti-Vα7.2 and either MR1-Ac-
6FP or MR1-5-OP-RU tetramer. In the next three panels, CD3
+
 Vα7.2
+
 MR1-5-OP-RU tetramer
+
 
MAIT cells were analyzed for CD4, CD8, CD161, CD218 and CD27 expression. (b) Graph depicts 
percentage MR1-5-OP-RU tetramer
+
 cells of total Vα7.2
+
 population in thymus, cord blood, young 
and adult peripheral blood. Data shows 9 samples for cord, young and adult blood and 12 thymus 
samples. (c) Percentages of CD161
-
CD218
-
 subset of total MAIT cells in thymus, cord blood, young 
and adult peripheral blood. Sample size as per b. (d) Percentages of CD4
+
CD8
+
, CD4
+
CD8
-
, and 
CD4
-
CD8
+
 MAIT cells in human thymus and young peripheral blood. Donor matched samples are 
indicated with a line. Data shows 9 samples for young peripheral blood and 12 thymus samples 
*<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. (e) Percentages of CD27
-
CD161
-
, CD27
+
CD161
-
, and CD161
+
 MAIT cells from 5 thymus samples, 4 cord blood samples and 
peripheral blood samples from 4 young and 5 adult donors. (f) CD4/CD8 co-receptor and PLZF 
expression on stage 1 (CD161
-
CD27
-
) cells in blue, stage 2 (CD161
-
CD27
+
) cells in green and stage 
3 cells  (CD161
+
CD27
-/+
) in red. 
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Cell TRAV TRAJ CDR3 alpha TRBV TRBJ CDR3 beta 
Stage 1 CD24+ CD44- MR1-5-OP-RU+ TCRβ+ 
1 TRAV1 TRAJ33 CAVRDSNYQLIW  TRBV13 TRBJ1-3 CASGDASXSGNTLYF 
2 TRAV1 TRAJ33 CAVTDSNYQLIW TRBV13-3 TRBJ2-1 CASSEQGGYAEQFF 
3 TRAV1 TRAJ33 CAVRDSNYQLIW  TRBV13-2 TRBJ2-5 CASGGWGFQDTQYF 
4 TRAV1 TRAJ33 CAVRXXNYXLIW TRBV13-3 N.D. 
5 TRAV1 TRAJ33 CAVRDRDYQLIW TRBV19 TRBJ1-6 
6 i) TRAV1 
ii) TRAV9 
i) TRAJ33 
ii) TRAJ29 
CAPMDSNYQLXW TRBV13-2 N.D. 
7 i) TRAV1 
ii) TRAV7 
TRAJ33 CAVRDSNYQLIW TRBV13-2 TRBJ2-5 CASGDGGGWDTQYF 
8 TRAV1 TRAJ33 CAVRDSNYQLIW TRBV13-3 TRBJ1-6 CASSDAGVNSPLYF 
9 TRAV1 TRAJ33 CAVSNSNYQLIW TRBV13-2 TRBJ2-1 CASGDGDSYAEQFF 
10 TRAV1 TRAJ33 CAVRDSNYQLIW TRBV13-2 TRBJ2-3 CASGDGDSAETLYF 
11 TRAV1 TRAJ33 CAVRDSNYQLIW TRBV13-2 TRBJ2-3 CASGGDGDSAETLYF 
12 TRAV1 TRAJ33 CAVMDSNYQLIW TRBV13-2 TRBJ2-1 CASGDGDSYAEQFF 
13 TRAV1 TRAJ33 CAVRDSNYQLIW TRBV13-3 TRBJ2-7 CASSAGTSSYEQYF 
Stage 3 CD24- CD44+ MR1-5-OP-RU+ TCRβ+ 
14 TRAV1 TRAJ33 CAVRDSNYQLIW TRBV13-3 TRBJ2-2 CASSDKGDTGQLYF 
15 TRAV1 TRAJ33 CAVLDSNYQLIW  TRBV13-3 TRBJ1-6 CASSDAGVNSPLYF 
16 TRAV1 TRAJ33 CAVMDSNYQLIW TRBV19 TRBJ2-7 CASSPGLESSYEQYF 
17 TRAV1 TRAJ33 CAVKDSNYXLIW TRBV13-3 TRBJ2-2 CASTRTENTGQLYF 
 
TCR sequences of mouse MAIT cell subsets.  
MR1-5-OP-RU tetramer+ stage 1 CD24+CD44- and stage 3 CD24-CD44+ MAIT cells were sorted as 
single cells and  their TCR-α and β chains were determined using single cell TCR sequencing. X 
defines undetermined amino acid. 
  
Supplementary Table 1 
Phenotypic characteristics of stage 1 and stage 3 MAIT cells in mice.  
Stage 1 and stage 3 MAIT cells were labeled with antibodies for a panel of phenotypic markers and 
analyzed by flow cytometry. 
 
Supplementary Table 2 
Stage 1 CD24+CD44- Stage 3 CD24-CD44+ 
CD4 and CD8 CD4 or CD4+CD8+ CD4+ or CD8+ or CD4-CD8- 
PLZF Negative/low Positive 
CD161 (NK1.1) Negative/low Low to Positive 
CD62L Intermediate Negative 
CD69 Positive Negative 
CD103 Negative Mostly Positive 
CD122 (IL-2R) Negative Intermediate 
CD127 (IL-7R) Negative Positive 
CD218 (IL-18R) Negative Positive 
CD278 (ICOS) Negative/low Positive 
Thymic MAIT cell subsets in Vα19 transgenic mice.  
Flow cytometry analysis of MR1-5-OP-RU tetramer reactive MAIT cells for expression of CD24 and 
CD44 in adult Vα19 transgenic mouse thymus. Data are representative of 3 independent experiments. 
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